(Q38199723)

30 August 2017

title

Brief overview of selected approaches in targeting pancreatic adenocarcinoma (English)

1 reference

30 August 2017

1 reference

Christopher S Gondi

2

0 references

author name string

Wesley R Samore

series ordinal

1

1 reference

30 August 2017

language of work or name

English

0 references

publication date

27 March 2014

1 reference

Expert Opinion on Investigational Drugs

30 August 2017

published in

1 reference

30 August 2017

volume

23

1 reference

30 August 2017

issue

6

1 reference

30 August 2017

page(s)

793-807

1 reference

30 August 2017

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Pancreatic cancer: a comprehensive review and update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Targeting the Ras-ERK pathway in pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Notch signaling in pancreatic cancer: oncogene or tumor suppressor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Ras/MAPK signaling from endomembranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Targeting protein prenylation in progeria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Mutant KRAS is a druggable target for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

MEK and the inhibitors: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Targeting EGFR in pancreatic cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

EGF receptor trafficking: consequences for signaling and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Cetuximab: still an option in the treatment of pancreatic cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Diffusion and convection in collagen gels: implications for transport in the tumor interstitium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Effective tumor regression by anti-neovascular therapy in hypovascular orthotopic pancreatic tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

The stromal compartments in pancreatic cancer: are there any therapeutic targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Prognostic impact of hyaluronan and its regulators in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Hyaluronic acid-coated liposomes for active targeting of gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Biology and clinical applications of pancreatic cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Targeting MET in cancer: rationale and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

The emerging role of MET/HGF inhibitors in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Influence of cytidine deaminase on antitumor activity of 2'-deoxycytidine analogs in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Hepatocyte-specific c-Met deletion disrupts redox homeostasis and sensitizes to Fas-mediated apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Urokinase-type plasminogen activator increases hepatocyte growth factor activity required for skeletal muscle regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Plasmin-mediated proteolysis is required for hepatocyte growth factor activation during liver repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Epigenetic deregulation of the COX pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Prostaglandins and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Epithelial-mesenchymal plasticity in carcinoma metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Spatiotemporal expression of Notch receptors and ligands in developing mouse placenta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Notch signaling controls multiple steps of pancreatic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

The love-hate relationship between Ras and Notch.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

γ-Secretase inhibitors and modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

A phase 3 trial of semagacestat for treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Therapeutic antibody targeting of individual Notch receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Targeting notch signaling pathway in cancer: clinical development advances and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Dll4-Notch signaling in regulation of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

The promise and failures of epigenetic therapies for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Acetylation and deacetylation of non-histone proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Targeting developmental regulators of zebrafish exocrine pancreas as a therapeutic approach in human pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

The anti-tumor effect of HDAC inhibition in a human pancreas cancer model is significantly improved by the simultaneous inhibition of cyclooxygenase 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.902933

Non-coding RNA production by RNA polymerase III is implicated in cancer

21 January 2018

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.1038/NRC2539

Identifiers

DOI

10.1517/13543784.2014.902933

1 reference

30 August 2017

1 reference